A Randomized Controlled Trial of SP-01 (Granisetron Transdermal Delivery System) in Chemotherapy-induced Nausea and Vomiting

Inclusion Criteria: * Male or female aged ≥ 18years * Histologically and/or cytologically confirmed cancer * The physical status score ECOG ≤ 2 * Life expectancy of ≥3 months * Will receive multi-day ME/HE chemotherapy (≥2 days) with the emetogenic potential of level 3-5 * In accordance with the indication of chemotherapy and basic requirements; * Peripheral Haematology: Hb ≥ 9.0 g/dL, absolute neutrophil count ≥ 1.5×10e9/L, platelet count ≥ 80×10e9/L * Blood biochemistry: Total bilirubin \< 1.25×ULN, ALT and AST ≤ 2.5×ULN; if liver metastasis, ALT and AST \< 5×ULN, Creatinine ≤ 1×ULN, basic normal serum electrolyte (Na, Ka, Cl, Ca) * Other important organs function normally * Subjects voluntarily participate and signed the informed consent form